Endocrine System — Comprehensive Checklist
Hierarchical breakdown: Function → Axis/Pathway → Gland/Tissue → Cells/Hormones/Structures
Organisational principle: Functional first, anatomical second. The endocrine system is organised by regulatory axes and biochemical pathways, not by anatomical location. Glands spanning multiple body regions (hypothalamus → pituitary → adrenal) are grouped by their shared functional circuit. Anatomical detail is nested within each functional grouping.
1. Hypothalamus (Neuroendocrine)
Function: The interface between the nervous system and endocrine system. Converts neural signals into hormonal signals. Receives input from limbic system (emotions), retina (light/dark), visceral afferents (gut, cardiovascular), temperature sensors, and circulating hormones (feedback). Outputs releasing/inhibiting hormones via the portal system and neurohypophyseal hormones via axonal transport.
1.1 Releasing / Inhibiting Hormones (Hypophysiotropic)
- TRH (Thyrotropin-Releasing Hormone) — paraventricular nucleus; stimulates TSH and prolactin release; tripeptide; degraded rapidly (half-life ~5 min); inhibited by T3/T4 (negative feedback)
- CRH (Corticotropin-Releasing Hormone) — paraventricular nucleus; stimulates ACTH release (HPA axis); 41-amino acid peptide; potentiated by vasopressin; activated by stress, inflammation, hypoglycaemia; inhibited by cortisol
- GnRH (Gonadotropin-Releasing Hormone) — preoptic area, arcuate nucleus; stimulates FSH and LH release; must be pulsatile (continuous → downregulation, basis of GnRH agonist therapy); pulse frequency determines FSH vs LH ratio; inhibited by sex steroids
- GHRH (Growth Hormone-Releasing Hormone) — arcuate nucleus; stimulates GH release; 44-amino acid peptide; inhibited by somatostatin and IGF-1
- Somatostatin (GHIH — Growth Hormone-Inhibiting Hormone) — periventricular nucleus; inhibits GH and TSH release; also produced in gut (D-cells) and pancreas (δ-cells); universal “brake” on secretion
- Dopamine (Prolactin-Inhibiting Factor / PIF) — arcuate nucleus (tuberoinfundibular pathway); tonically inhibits prolactin release; dopamine is the only major hypothalamic inhibitor (prolactin is the only pituitary hormone under tonic inhibition); stalk section → hyperprolactinaemia (loss of dopamine delivery)
1.2 Neurohypophyseal Hormones (synthesised in hypothalamus, stored in posterior pituitary)
- ADH / Vasopressin (AVP) — supraoptic nucleus (primarily), paraventricular nucleus; nonapeptide; stored in Herring bodies; released in response to increased plasma osmolality (detected by hypothalamic osmoreceptors) or decreased blood volume (detected by baroreceptors); acts on V2 receptors (collecting duct aquaporin-2 insertion → water reabsorption) and V1a receptors (vascular smooth muscle → vasoconstriction)
- Oxytocin — paraventricular nucleus (primarily), supraoptic nucleus; nonapeptide; positive feedback release (Ferguson reflex); triggers uterine contraction (parturition), milk ejection (let-down reflex), social bonding, trust; structurally differs from vasopressin by only 2 amino acids
1.3 Key Hypothalamic Nuclei (Endocrine-Relevant)
- Supraoptic nucleus (SON) — primary ADH production; magnocellular neurons project to posterior pituitary
- Paraventricular nucleus (PVN) — dual function: magnocellular (ADH, oxytocin → posterior pituitary) and parvocellular (CRH, TRH → portal system to anterior pituitary)
- Arcuate nucleus (ARC) — appetite regulation (POMC/CART = anorexigenic vs NPY/AgRP = orexigenic); GnRH neurons; KNDy neurons (kisspeptin/neurokinin B/dynorphin → GnRH pulse generator); GHRH neurons; dopamine (tuberoinfundibular)
- Ventromedial nucleus (VMN) — satiety centre; destruction → hyperphagia and obesity; also involved in fear responses and sexual behaviour
- Lateral hypothalamic area — hunger centre; produces orexin/hypocretin (wakefulness, appetite); destruction → aphagia; orexin neuron loss → narcolepsy
- Suprachiasmatic nucleus (SCN) — master circadian pacemaker; receives retinal input (retinohypothalamic tract, melanopsin-containing retinal ganglion cells); controls pineal melatonin via multisynaptic pathway (SCN → PVN → intermediolateral column → superior cervical ganglion → pineal); drives cortisol, temperature, and hormone rhythms
- Preoptic area — thermoregulation (fever response via PGE2); GnRH neuron cell bodies migrate here from olfactory placode during embryogenesis; sexual dimorphic nucleus
- Dorsomedial nucleus (DMN) — integrates circadian and feeding signals; modulates HPA axis stress response
- Periventricular nucleus — primary source of hypothalamic somatostatin (GHIH); adjacent to third ventricle; somatostatin produced here enters the portal system to tonically inhibit GH and TSH release from anterior pituitary; also receives input from arcuate nucleus, integrating growth and metabolic signals; damage or lesions → loss of GH inhibition → potential GH hypersecretion
1.4 Hypothalamic-Hypophyseal Portal System
Function: Dedicated vascular link ensuring hypothalamic releasing hormones reach the anterior pituitary at high concentration without systemic dilution. This portal system (two capillary beds connected by veins) is the reason tiny amounts of hypothalamic hormones can control pituitary output.
- Superior hypophyseal arteries — from internal carotid; supply median eminence
- Primary capillary plexus (median eminence) — fenestrated capillaries where hypothalamic hormones enter the blood; outside the blood-brain barrier
- Hypophyseal portal veins (long portal vessels) — carry hormone-enriched blood down the pituitary stalk
- Secondary capillary plexus (anterior pituitary) — fenestrated capillaries bathing pituitary cells; hormones bind receptors on target cell types
- Short portal vessels (posterior → anterior pituitary) — allow posterior pituitary hormones (especially vasopressin) to modulate anterior pituitary function directly; vasopressin potentiates CRH-driven ACTH release
2. Pituitary Gland (Hypophysis)
Function: The “master gland” — translates hypothalamic commands into circulating hormones that regulate peripheral glands (thyroid, adrenals, gonads) and directly control growth, lactation, and water balance. Anterior pituitary synthesises its own hormones; posterior pituitary stores and releases hypothalamic hormones.
2.1 Anterior Pituitary (Adenohypophysis)
Function: Synthesises 6 major hormones from 5 cell types. Derived from oral ectoderm (Rathke’s pouch). Regulated by hypothalamic releasing/inhibiting hormones via the portal system and by peripheral hormone feedback loops.
Pars Distalis (Main Body)
| Cell Type | % | Hormone | Function | Regulated by |
|---|---|---|---|---|
| Somatotrophs | 40-50% | GH (Growth Hormone / Somatotropin) | Linear growth (epiphyseal plates); hepatic IGF-1 secretion; protein synthesis; lipolysis; insulin antagonism | GHRH (+), Somatostatin (−), IGF-1 (−), Ghrelin (+) |
| Lactotrophs | 10-25% | Prolactin (PRL) | Mammary gland development and milk production; immune modulation; reproductive function (inhibits GnRH at high levels → amenorrhoea) | Dopamine (−, tonic), TRH (+), Oestrogen (+) |
| Corticotrophs | 15-20% | ACTH (from POMC cleavage) | Stimulates adrenal cortex (mainly zona fasciculata → cortisol); trophic maintenance of adrenal cortex | CRH (+), Vasopressin (+), Cortisol (−) |
| β-LPH, β-Endorphin, MSH | POMC co-products: β-endorphin (analgesia, stress), MSH (melanocyte stimulation → skin pigmentation; elevated in Addison’s disease/ACTH excess) | |||
| Thyrotrophs | 3-5% | TSH (Thyroid-Stimulating Hormone) | Stimulates thyroid follicular cells → T4/T3 synthesis and release; trophic maintenance of thyroid | TRH (+), T3/T4 (−), Somatostatin (−) |
| Gonadotrophs | 10-15% | FSH (Follicle-Stimulating Hormone) | Female: follicular development, granulosa cell aromatase (→ oestradiol). Male: Sertoli cell function, spermatogenesis support | GnRH (+, pulsatile), Inhibin (−), Oestradiol (−, except mid-cycle surge: +) |
| LH (Luteinising Hormone) | Female: ovulation trigger, corpus luteum formation, theca cell androgens. Male: Leydig cell testosterone production | GnRH (+, pulsatile), Testosterone (−), Progesterone (−) | ||
| Folliculostellate | scattered | Paracrine (IL-6, follistatin, VEGF) | Local regulation of pituitary cell communication and angiogenesis; not classical endocrine cells |
Pars Tuberalis
- Wraps around infundibular stalk — thin sleeve of cells
- Gonadotrophs and thyrotrophs — contribute to basal hormone output
- Melatonin receptors (MT1) — highest MT1 density in the pituitary; mediates photoperiodic regulation of reproduction and TSH; interface between circadian and reproductive systems
Pars Intermedia (rudimentary in humans)
- MSH-producing cells (melanotrophs) — functional in fetal life; vestigial in adults; prominent in other species (skin colour regulation)
- Colloid-filled cysts (Rathke’s cleft remnants) — embryological remnant; can enlarge → Rathke’s cleft cyst (usually asymptomatic, occasionally compresses pituitary)
2.2 Posterior Pituitary (Neurohypophysis)
Function: Neural extension of the hypothalamus — does not synthesise hormones. Stores and releases ADH and oxytocin produced in hypothalamic nuclei. Derived from neuroectoderm (diencephalon).
Pars Nervosa
- Herring bodies — dilated axon terminals containing neurosecretory granules (ADH and oxytocin); visible on histology as eosinophilic swellings
- Pituicytes — glial-like support cells (modified astrocytes); regulate hormone release by modulating access of axon terminals to perivascular space
- Oxytocin release — uterine contraction (positive feedback during labour), milk ejection (neurohumoral reflex: suckling → afferent nerves → PVN → oxytocin pulse → myoepithelial contraction), social bonding and trust
- ADH/Vasopressin release — water reabsorption: V2 receptors on collecting duct principal cells → AQP2 insertion → water permeability (concentrated urine); vasoconstriction: V1a receptors on vascular smooth muscle (high-dose effect, haemorrhagic shock); deficiency → diabetes insipidus (dilute polyuria)
Infundibulum (Pituitary Stalk)
- Hypothalamo-hypophyseal tract — ~100,000 unmyelinated axons from SON and PVN carrying neurosecretory granules to pars nervosa; axonal transport rate ~2-3 mm/hour
- Portal vessels — long and short portal vessels traversing the stalk; stalk compression/transection disrupts portal flow → loss of hypothalamic control over anterior pituitary
3. Pineal Gland (Hypothalamic-Commanded Circadian Effector)
Anatomical note: The pineal is an epithalamic structure (posterior to third ventricle, attached to habenular commissure), not part of the hypothalamus. It is grouped here because it is functionally downstream of the SCN → superior cervical ganglion → pineal sympathetic innervation pathway. It has no portal system connection and no classical axis membership. Its output (melatonin) feeds back to the SCN.
Function: Transduces photoperiod (day length) information into a hormonal signal (melatonin). Darkness stimulates melatonin production; light inhibits it. Melatonin synchronises circadian rhythms, promotes sleep, and in many species regulates seasonal reproduction. In humans, it modulates sleep-wake cycles, core body temperature rhythm, and has immunomodulatory and antioxidant roles.
3.1 Structure
- Pinealocytes (main secretory cells) — contain serotonin and melatonin-synthesising enzymes; sympathetic innervation (noradrenaline via β1 receptors) drives melatonin synthesis at night
- Interstitial (glial) cells — support and modulate pinealocyte function; GFAP-positive (astrocyte-like)
- Perivascular phagocytes — immune surveillance within the gland
- Corpora arenacea (brain sand / acervuli) — calcified deposits of hydroxyapatite and calcium carbonate; increase with age; visible on skull X-ray (clinical landmark for midline); do not impair function
- No blood-brain barrier (circumventricular organ) — rich blood supply; melatonin secreted directly into blood and CSF
3.2 Hormones
- Melatonin (N-acetyl-5-methoxytryptamine)
- Circadian rhythm regulation — peak secretion 02:00-04:00; duration proportional to night length (seasonal signal)
- Sleep-wake cycle — promotes sleep onset by acting on SCN (MT1 → neuronal inhibition, MT2 → phase shifting) and directly on thalamic sleep circuits
- Seasonal reproduction (photoperiodism) — in seasonal breeders, melatonin duration signals day length to HPG axis; in humans, effect is subtle but melatonin does modulate GnRH
- Antioxidant properties — direct free radical scavenger (more potent than glutathione); stimulates antioxidant enzyme expression (SOD, GPx, catalase)
- Immunomodulatory — enhances Th1 responses, increases NK cell activity, opposes cortisol-mediated immunosuppression
- Synthesis pathway: Tryptophan → 5-HTP (tryptophan hydroxylase) → Serotonin (AADC) → NAS (AANAT, rate-limiting, noradrenaline-driven) → Melatonin (HIOMT)
- Receptors: MT1 (SCN, pars tuberalis, blood vessels, immune cells), MT2 (retina, SCN, hippocampus)
- Dimethyltryptamine (DMT) — trace amounts; endogenous hallucinogen; significance debated; may be produced more widely (lungs, retina, brain) than just pineal
- Serotonin (precursor, daytime) — pineal serotonin is highest concentration in the body during daytime; converted to melatonin at night; not released as a hormone from pineal
4. Thyroid Gland
Function: Produces thyroid hormones (T3/T4) that set the basal metabolic rate of virtually every cell in the body. Essential for normal growth, brain development (cretinism if deficient in infancy), thermogenesis, cardiac output, and gut motility. Also produces calcitonin (calcium regulation). The thyroid is the only endocrine gland that stores large amounts of pre-formed hormone (as colloid — weeks-months supply).
4.1 Gross Anatomy
- Right lobe — typically larger than left
- Left lobe
- Isthmus — connects lobes across tracheal rings 2-4
- Pyramidal lobe (present in ~50%) — embryological remnant of thyroglossal duct; ascends from isthmus toward hyoid
- Capsule (true and false/surgical) — true capsule: thin fibrous; false capsule: pretracheal fascia layer; surgical plane between them
- Ligament of Berry (posterior suspensory) — attaches thyroid to cricoid cartilage and tracheal rings; contains terminal branches of inferior thyroid artery and is intimately related to recurrent laryngeal nerve (surgical hazard)
4.2 Follicular Cells (Thyrocytes)
Function: Synthesise, store, and release thyroid hormones. Unique among endocrine cells in using iodine and storing hormone extracellularly as colloid.
- Thyroglobulin synthesis — large glycoprotein (660 kDa) serving as scaffold for hormone synthesis; synthesised in rough ER, glycosylated, secreted into follicular lumen
- Iodide uptake (NIS — sodium-iodide symporter) — basolateral membrane; concentrates iodide 20-40× over plasma; TSH upregulates; inhibited by perchlorate, pertechnetate (diagnostic/therapeutic implications)
- Thyroid peroxidase (TPO) — apical membrane; catalyses iodination of thyroglobulin tyrosine residues (MIT, DIT) and coupling (DIT+DIT→T4, DIT+MIT→T3); target of anti-TPO autoantibodies in Hashimoto’s thyroiditis
- T4 (Thyroxine / Tetraiodothyronine) — ~90% of thyroid output; prohormone; long half-life (6-7 days); 99.97% protein-bound (TBG, albumin, transthyretin); converted to T3 peripherally
- T3 (Triiodothyronine) — ~10% of thyroid output, but 3-5× more biologically active than T4; short half-life (1 day); binds nuclear thyroid hormone receptors (TR-α, TR-β) → gene transcription; most T3 is from peripheral T4→T3 conversion
- rT3 (Reverse T3) — inactive metabolite of T4; produced by D3 deiodinase; elevated in sick euthyroid syndrome (non-thyroidal illness), starvation; represents diversion of T4 away from active T3
- Colloid (thyroglobulin storage in follicular lumen) — weeks to months of preformed hormone; buffer against iodine deficiency; TSH stimulates colloid endocytosis → lysosomal proteolysis → T3/T4 release
- Pendrin (apical iodide transporter) — effluxes iodide into follicular lumen for incorporation into thyroglobulin; mutations → Pendred syndrome (sensorineural deafness + goitre)
- Deiodinases (D1, D2, D3) — peripheral T4→T3 conversion: D1 (liver, kidney — bulk conversion), D2 (brain, pituitary, BAT — local activation, maintains CNS T3), D3 (placenta, brain — inactivation, T4→rT3, T3→T2, protects fetal brain from excess thyroid hormone)
4.3 Parafollicular Cells (C-cells)
Function: Produce calcitonin in response to hypercalcaemia. Calcitonin lowers serum calcium by inhibiting osteoclast bone resorption. Physiological role in adults is minor (thyroidectomy patients maintain normal calcium). Clinically important as tumour marker (medullary thyroid carcinoma).
- Calcitonin — 32-amino acid peptide; lowers serum calcium by inhibiting osteoclast activity (binds calcitonin receptor on osteoclasts → reduces bone resorption); also increases renal calcium excretion; physiological importance debated in adults (redundant with PTH system); tumour marker for medullary thyroid carcinoma (MTC, C-cell neoplasm)
- Neural crest-derived — unlike follicular cells (endoderm); migrate from ultimobranchial body during embryogenesis
- Scattered between follicles and within follicular basement membrane — represent <1% of thyroid cells; concentrated at junction of upper and middle thirds of each lobe
4.4 Thyroid Vasculature
- Superior thyroid artery (from external carotid) — supplies upper pole; closely related to external branch of superior laryngeal nerve
- Inferior thyroid artery (from thyrocervical trunk) — supplies lower pole; intimately related to recurrent laryngeal nerve at its crossing point (key surgical landmark)
- Thyroid ima artery (inconstant, from brachiocephalic/aorta) — present in ~3-10%; supplies inferior thyroid/isthmus; arises directly from brachiocephalic trunk or aortic arch, crossing anterior to the trachea; functionally significant because it provides an alternative blood supply to the isthmus that persists when superior/inferior thyroid arteries are ligated; must be identified and controlled before tracheostomy or thyroid surgery to avoid haemorrhage from an unexpected midline vessel
- Superior/middle/inferior thyroid veins — superior and middle drain to internal jugular; inferior drains to brachiocephalic veins
4.5 Associated Structures
- Recurrent laryngeal nerves (posterior, at risk in surgery) — motor to all intrinsic laryngeal muscles except cricothyroid; injury → hoarseness (unilateral) or airway compromise (bilateral); runs in tracheoesophageal groove
- External branch of superior laryngeal nerve — motor to cricothyroid (tensor of vocal cord); injury → voice fatigue, loss of high pitch; runs with superior thyroid artery
5. Parathyroid Glands
Function: Maintain serum calcium within a narrow range (2.2-2.6 mmol/L) essential for neuromuscular function, cardiac conduction, coagulation, and bone mineralisation. PTH is the minute-to-minute regulator of calcium — acts on bone (resorption), kidney (reabsorption, phosphate excretion, vitamin D activation), and indirectly on gut (via vitamin D → calcium absorption). Hypoparathyroidism → tetany, seizures; hyperparathyroidism → “bones, stones, abdominal groans, psychic moans.”
5.1 Anatomy
- Superior parathyroids (paired) — derived from 4th pharyngeal pouch; more consistent position (posterior to upper thyroid pole); less likely to be ectopic
- Inferior parathyroids (paired) — derived from 3rd pharyngeal pouch (with thymus); longer embryological migration → more variable position (thyroid capsule, thyrothymic ligament, anterior mediastinum/thymus)
- Supernumerary glands (5-13% of population) — usually in thymus or mediastinum; important in recurrent hyperparathyroidism after surgery
- Ectopic locations (mediastinal, intrathyroidal, retrooesophageal) — relevant for failed parathyroidectomy; sestamibi scan for localisation
5.2 Chief Cells (Principal Cells)
Function: The calcium sensor and PTH factory. Calcium-sensing receptor (CaSR) on the cell membrane detects extracellular calcium concentration. Low calcium → increased PTH secretion within seconds. High calcium → suppressed PTH.
- PTH (Parathyroid Hormone / Parathormone) — 84-amino acid peptide; half-life ~4 minutes; most rapid-response calcium regulator
- Raises serum calcium via three mechanisms:
- Stimulates osteoclast activity (bone resorption) — indirect: PTH acts on osteoblasts → RANKL → osteoclast activation (osteoclasts have no PTH receptors); releases calcium and phosphate from bone
- Increases renal calcium reabsorption (DCT) — direct action on distal convoluted tubule; simultaneously increases phosphate excretion (proximal tubule) to prevent calcium-phosphate precipitation
- Stimulates 1α-hydroxylase → active vitamin D (1,25-dihydroxycholecalciferol / calcitriol) — in proximal tubule; calcitriol then increases intestinal calcium and phosphate absorption (delayed effect, hours-days)
- Calcium-sensing receptor (CaSR) — G-protein coupled receptor; senses extracellular Ca²+; activating mutations → hypoparathyroidism; inactivating mutations → familial hypocalciuric hypercalcaemia; drug target: cinacalcet (calcimimetic)
5.3 Oxyphil Cells
- Function debated (may produce PTH and PTHrP in pathological states) — contain PTH mRNA; possibly active in secondary hyperparathyroidism
- Increase with age — progressively replace chief cells; predominate after age 40
- Mitochondria-rich — distinctive eosinophilic, granular cytoplasm due to dense mitochondria; oncocytic variant
6. Adrenals & Gonads
Organisational note: Adrenal cortex and gonads share the cholesterol → pregnenolone steroidogenic pathway (CYP11A1/StAR). They are grouped together because the same enzyme cascade branches into mineralocorticoids, glucocorticoids, and sex steroids depending on which tissue-specific enzymes are expressed. Cross-talk is constant: cortisol suppresses GnRH (stress amenorrhoea), adrenal DHEA-S is the largest circulating steroid pool and undergoes peripheral conversion to sex hormones. The adrenal medulla and paraganglia are included as the catecholamine-producing chromaffin tissue system. Gonadal reproductive anatomy (follicular apparatus, seminiferous tubules) is detailed in the Sexual Reproduction checklist; this section covers hormonal outputs and regulatory axes.
6.1 Shared Steroidogenesis Pathway
Function: The universal biochemical backbone from which all steroid hormones are built. Every steroid-producing tissue starts with the same substrate (cholesterol) and first enzyme (CYP11A1). What determines the final hormone product is which downstream enzymes each tissue expresses. This shared pathway explains why enzyme deficiencies (e.g., 21-hydroxylase deficiency = congenital adrenal hyperplasia) affect multiple hormone classes simultaneously.
6.1.1 Rate-Limiting Entry Step
- Cholesterol → Pregnenolone (StAR protein + CYP11A1/P450scc) — StAR (Steroidogenic Acute Regulatory protein) transports cholesterol across mitochondrial membrane (rate-limiting transport step); CYP11A1 (cholesterol side-chain cleavage enzyme) converts cholesterol to pregnenolone (rate-limiting enzymatic step); both steps occur in mitochondria; ACTH upregulates StAR acutely and CYP11A1 chronically
6.1.2 Branch Enzymes (Determine Final Product)
- CYP17 (17α-hydroxylase / 17,20-lyase) — gates entry to androgen and cortisol pathways; 17α-hydroxylase activity: pregnenolone → 17-OH-pregnenolone (both adrenal and gonad); 17,20-lyase activity: 17-OH-pregnenolone → DHEA (mainly adrenal reticularis and gonads); expressed in zona fasciculata, reticularis, and gonads; NOT in zona glomerulosa (so glomerulosa can only make aldosterone, not cortisol or androgens)
- CYP21 (21-hydroxylase) — gates mineralocorticoid and glucocorticoid pathways; progesterone → DOC and 17-OH-progesterone → 11-deoxycortisol; most common enzyme deficiency in congenital adrenal hyperplasia (~95% of cases); deficiency → cortisol/aldosterone deficiency + androgen excess (shunted precursors → adrenal androgens)
- CYP11B1 (11β-hydroxylase) — 11-deoxycortisol → cortisol; zona fasciculata only; deficiency → cortisol deficiency + DOC excess (hypertension) + androgen excess
- CYP11B2 (aldosterone synthase) — corticosterone → aldosterone (via 18-hydroxylation and 18-oxidation); zona glomerulosa only; regulated by angiotensin II and K+, not ACTH
- CYP19 (aromatase) — converts androgens → oestrogens (androstenedione → oestrone, testosterone → oestradiol); expressed in granulosa cells, placenta, adipose tissue, brain, bone; aromatase inhibitors (letrozole, anastrozole) used in breast cancer treatment
- 3β-HSD (3β-hydroxysteroid dehydrogenase) — converts Δ5 steroids to Δ4 steroids (pregnenolone → progesterone, DHEA → androstenedione); essential in all steroid-producing tissues
- 17β-HSD (17β-hydroxysteroid dehydrogenase) — androstenedione → testosterone; oestrone → oestradiol; multiple isoforms with tissue-specific expression and directionality
6.1.3 Pathway Branches
- Mineralocorticoid branch: Pregnenolone → Progesterone (3β-HSD) → DOC (CYP21) → Corticosterone (CYP11B1) → Aldosterone (CYP11B2) — zona glomerulosa only; no CYP17 expression ensures this pathway cannot produce cortisol or androgens
- Glucocorticoid branch: Pregnenolone → 17-OH-Pregnenolone (CYP17) → 17-OH-Progesterone (3β-HSD) → 11-Deoxycortisol (CYP21) → Cortisol (CYP11B1) — zona fasciculata; ACTH-driven
- Androgen branch: Pregnenolone → 17-OH-Pregnenolone (CYP17-hydroxylase) → DHEA (CYP17-lyase) → Androstenedione (3β-HSD) → Testosterone (17β-HSD) — zona reticularis and gonads
- Oestrogen conversion: Testosterone → Oestradiol (CYP19/aromatase) — granulosa cells (ovary), adipose tissue, brain, bone; peripheral aromatisation is primary oestrogen source post-menopause
- DHT conversion: Testosterone → Dihydrotestosterone (5α-reductase type II) — prostate, external genitalia, hair follicles, skin; 2-3× more potent androgen receptor binding than testosterone; 5α-reductase inhibitors (finasteride) used for BPH and male pattern baldness
6.2 Adrenal Cortex (Mesodermal Origin)
Function: Three concentric zones producing three classes of steroid hormones. Mnemonic: “GFR — salt, sugar, sex” (Glomerulosa = mineralocorticoids, Fasciculata = glucocorticoids, Reticularis = androgens). The cortex is essential for life — complete cortical failure (Addisonian crisis) is fatal without replacement.
6.2.1 Zona Glomerulosa (Outer)
Function: Mineralocorticoid production — regulates sodium/potassium balance and blood volume. Primarily controlled by the Renin-Angiotensin-Aldosterone System (RAAS) and serum potassium, NOT by ACTH (though ACTH has permissive role).
- Mineralocorticoids
- Aldosterone (primary) — most potent mineralocorticoid
- Sodium retention, potassium excretion — binds mineralocorticoid receptor (MR) in distal nephron principal cells → upregulates ENaC (epithelial sodium channel) and Na+/K+-ATPase → sodium reabsorption, potassium secretion
- Acts on distal nephron (DCT and collecting duct), also colon, salivary glands, sweat glands
- Regulated by RAAS (renin from JG cells → angiotensin I → ACE → angiotensin II → zona glomerulosa) and serum K+ (direct stimulation); NOT primarily by ACTH
- Excess → Conn’s syndrome (primary hyperaldosteronism: hypertension, hypokalaemia); deficiency → salt wasting, hyperkalaemia
- Deoxycorticosterone (DOC) — weak mineralocorticoid; precursor; accumulates in CYP11B1 deficiency
- Aldosterone (primary) — most potent mineralocorticoid
6.2.2 Zona Fasciculata (Middle — Widest)
Function: Glucocorticoid production — the body’s primary stress response hormone and metabolic regulator. Directly controlled by ACTH from the anterior pituitary (HPA axis). Zone accounts for ~80% of cortical mass.
- Glucocorticoids
- Cortisol (primary) — the essential glucocorticoid
- Gluconeogenesis — stimulates hepatic glucose production from amino acids and glycerol; raises blood glucose
- Protein catabolism — mobilises amino acids from muscle; redistributes to liver for gluconeogenesis
- Lipolysis — mobilises fatty acids from adipose; redistributes fat (truncal obesity in Cushing’s)
- Anti-inflammatory / immunosuppressive — inhibits NF-κB, reduces prostaglandin and leukotriene synthesis, decreases lymphocyte proliferation, induces lymphocyte apoptosis; basis of therapeutic corticosteroid use
- Circadian rhythm — peak 06:00-08:00 (cortisol awakening response), nadir midnight; driven by SCN → CRH pulsatility
- Stress response — HPA activation by physical/psychological stress, hypoglycaemia, infection, surgery
- Permissive effects on catecholamines — required for normal adrenergic receptor expression and vascular tone; adrenal insufficiency → refractory hypotension
- Corticosterone — weaker glucocorticoid; precursor to aldosterone; primary glucocorticoid in rodents (not humans)
- Cortisone (inactive, converted peripherally) — 11β-HSD1 converts cortisone → cortisol (liver, adipose); 11β-HSD2 converts cortisol → cortisone (kidney — protects MR from cortisol activation)
- Cortisol (primary) — the essential glucocorticoid
- Regulated by ACTH (HPA axis) — CRH → ACTH → cortisol → negative feedback on CRH and ACTH; disruption → Cushing’s (excess) or Addison’s (deficiency)
6.2.3 Zona Reticularis (Inner)
Function: Adrenal androgen production. Produces weak androgens (DHEA, DHEA-S, androstenedione) that serve as precursors for peripheral conversion to testosterone and oestradiol. DHEA-S is the most abundant circulating steroid. Primary source of androgens in women and pre-pubertal children. Adrenarche (onset ~6-8 years) precedes gonadarche by ~2 years.
- Adrenal Androgens
- DHEA (Dehydroepiandrosterone) — weak androgen; precursor for peripheral conversion to testosterone and oestradiol; immunostimulatory (opposes cortisol immunosuppression); peaks at age 20-30, then declines (~2%/year — “adrenopause”)
- DHEA-S (DHEA-Sulfate) — sulphated form; long half-life (7-10 hours vs 30 min for DHEA); most abundant circulating steroid; marker of adrenal androgen production; stable throughout day (no diurnal variation)
- Androstenedione — intermediate potency androgen; converted to testosterone (17β-HSD) or oestrone (aromatase) in peripheral tissues; primary androgen substrate for post-menopausal oestrogen production
- Small amounts of testosterone and oestrogen — functionally significant in three contexts: (1) post-menopausal women: adrenal androgens become the primary substrate for peripheral aromatisation to oestrogens (adipose, bone, brain), maintaining residual oestrogen levels that protect bone density and cardiovascular function; (2) women with adrenal androgen excess (PCOS, late-onset CAH): adrenal testosterone contributes to hirsutism, acne, and anovulation; (3) breast cancer treatment: adrenalectomy or adrenal androgen suppression further reduces peripheral oestrogen conversion, hence the use of aromatase inhibitors that block this pathway
- Adrenarche (onset ~6-8 years) — maturation of zona reticularis; increased DHEA/DHEA-S production; drives pubic/axillary hair, body odour, mild acne; independent of HPG axis (distinct from gonadarche)
6.3 Gonadal Endocrine Function
Cross-reference: Gonadal reproductive anatomy (follicular apparatus, seminiferous tubule structure, corpus luteum lifecycle) is in the Sexual Reproduction checklist. This section covers hormonal outputs and their regulatory axes only.
Function: Sex steroid production for reproductive function, secondary sex characteristics, and anabolic effects. Controlled by HPG axis (GnRH → FSH/LH → gonadal steroids → feedback). The gonads are steroidogenic tissues that express the same core enzymes as adrenal cortex (§6.1) but with different enzyme profiles yielding different end products (predominantly sex steroids rather than corticosteroids).
6.3.1 Testicular Endocrine Cells
- Leydig cells (interstitial) — located between seminiferous tubules; respond to LH
- Testosterone — primary male sex hormone; most potent natural androgen
- Spermatogenesis (with FSH) — testosterone within tubules (maintained by ABP from Sertoli cells) is 50-100× higher than serum; essential for meiotic progression
- Secondary sex characteristics — voice deepening, facial/body hair, male-pattern fat distribution, penile growth
- Anabolic effects (muscle, bone) — increases muscle protein synthesis, stimulates periosteal bone growth, promotes epiphyseal closure (via aromatisation to oestradiol)
- Libido — direct CNS effects on sexual desire in both sexes
- DHT conversion (5α-reductase) — in prostate, skin, hair follicles; DHT drives prostate growth, male pattern baldness, external genital virilisation in utero
- Oestradiol conversion (aromatase) — in adipose, brain, bone; male oestradiol is essential for bone density and epiphyseal fusion
- Insulin-like Factor 3 (INSL3) — peptide hormone of the relaxin/insulin superfamily; constitutively produced by Leydig cells (not regulated by LH acutely — reflects Leydig cell differentiation status rather than acute stimulation); fetal function: binds RXFP2 receptor on gubernacular ligament → gubernacular swelling and shortening → transabdominal phase of testicular descent (INSL3 or RXFP2 mutations → cryptorchidism); adult function: promotes osteoblast differentiation and bone mineralisation (INSL3 knockout → reduced bone density); clinical utility: serum INSL3 is a direct marker of mature Leydig cell mass and function — more stable than testosterone (no pulsatility, no SHBG binding), used to assess Leydig cell reserve in hypogonadism and to monitor recovery after gonadotoxic therapy
- Testosterone — primary male sex hormone; most potent natural androgen
- Sertoli cells (seminiferous tubules) — respond to FSH; “nurse cells” for developing germ cells
- Inhibin B — negative feedback specifically on FSH (not LH); marker of spermatogenesis and Sertoli cell function
- Activin — stimulates FSH release; also local paracrine roles in spermatogenesis
- Anti-Mullerian Hormone (AMH) — fetal: regression of Mullerian ducts (prevents female internal genitalia development in 46,XY); post-natal: declines after puberty (testosterone suppresses); clinical marker of Sertoli cell function in paediatrics
- Androgen-Binding Protein (ABP) — concentrates testosterone within seminiferous tubules to levels needed for spermatogenesis (50-100× serum)
- Oestradiol (local aromatisation) — local regulation of spermatogenesis; excess oestrogen disrupts male fertility
- Blood-testis barrier (tight junctions) — isolates developing germ cells from immune system (germ cells express novel antigens after meiosis); breakdown → autoimmune orchitis, anti-sperm antibodies
6.3.2 Ovarian Endocrine Cells
- Theca interna cells (LH-driven) — outer layer of developing follicle
- Androstenedione, Testosterone — substrates for granulosa aromatase; two-cell two-gonadotropin model: LH drives theca androgen production, FSH drives granulosa aromatase
- Granulosa cells (FSH-driven) — inner layer surrounding oocyte
- Oestradiol (E2) — primary oestrogen; aromatisation of thecal androgens; drives endometrial proliferation, cervical mucus changes, LH surge (positive feedback at mid-cycle)
- Inhibin A & B — Inhibin B: dominant in follicular phase (FSH feedback); Inhibin A: dominant in luteal phase; selective FSH suppression without affecting LH
- AMH (Anti-Mullerian Hormone) — produced by small antral follicles; marker of ovarian reserve (declining AMH = diminishing follicle pool); used in fertility assessment and IVF planning
- Corpus luteum — transient endocrine organ formed from ruptured follicle after ovulation; has its own blood supply (neovascularisation)
- Progesterone (primary) — the “pregnancy hormone”
- Endometrial secretory transformation — converts proliferative endometrium to secretory (receptive to implantation)
- Maintains early pregnancy — prevents uterine contractions; supports decidualisation; immunomodulatory (shifts Th1→Th2)
- Thermogenic (raises basal body temperature ~0.3-0.5°C) — basis of BBT charting for ovulation tracking
- Oestradiol (secondary) — continues oestrogen production during luteal phase
- Inhibin A — luteal phase dominant; suppresses FSH to prevent new follicle recruitment during luteal phase
- Relaxin (in pregnancy) — softens cervix, relaxes pelvic ligaments; vasodilatory (increases GFR in pregnancy)
- Granulosa-lutein cells (large luteal cells) — primary progesterone producers; respond to LH
- Theca-lutein cells (small luteal cells) — produce androgens; respond to LH; can convert to progesterone production
- Progesterone (primary) — the “pregnancy hormone”
- Ovarian stroma
- Interstitial cells (androgen-producing) — derived from atretic follicle theca cells; continue producing androgens; contribute to post-menopausal androgen production
- Hilar cells (Leydig cell homologues) — located at the ovarian hilum where blood vessels and nerves enter; morphologically identical to testicular Leydig cells (contain Reinke crystalloids — hexagonal protein crystals diagnostic of Leydig-type cells); normal physiological role: low-level constitutive androgen production (testosterone, androstenedione) contributing to baseline circulating androgen pool in women; become relatively more significant post-menopause as follicular theca cells are depleted; responsive to LH stimulation; pathology: hilar cell tumours (pure Leydig cell tumours of the ovary) → virilisation (deepened voice, clitoromegaly, male-pattern hair), typically benign and unilateral; these cells represent the embryological homologue of testicular Leydig cells from the shared gonadal ridge origin
6.3.3 Placental Endocrine Function (Temporary)
Function: Temporary endocrine organ of pregnancy. Takes over steroid production from corpus luteum (luteal-placental shift ~week 8-12). Unique: lacks CYP17 → cannot produce androgens de novo; depends on fetal and maternal adrenal DHEA-S as androgen substrates for placental aromatase to produce oestrogens (feto-placental unit).
- hCG (Human Chorionic Gonadotropin) — maintains corpus luteum past its normal 14-day lifespan; structurally similar to LH; peaks at 8-10 weeks then declines; basis of pregnancy tests; drives first-trimester nausea; also stimulates fetal Leydig cells (testosterone for male genital development)
- hPL (Human Placental Lactogen / hCS) — insulin resistance (diverts glucose to fetus), maternal lipolysis (provides fatty acids to mother), mammary gland development; structurally similar to GH and prolactin; rises throughout pregnancy; gestational diabetes risk factor
- Progesterone (takes over from corpus luteum ~week 8-12) — maintains pregnancy; immunomodulatory; uterine quiescence
- Oestrogens (oestriol E3 predominant) — E3 requires fetal 16α-hydroxylation of DHEA-S (feto-placental unit); marker of fetal adrenal and liver function; E3 rises throughout pregnancy
- CRH (Placental) — unlike hypothalamic CRH, placental CRH increases with cortisol (positive feedback → “placental clock” theory of parturition timing); exponential rise near term
- Placental GH (GH-V variant) — replaces pituitary GH by mid-pregnancy; drives maternal IGF-1; insulin resistance
- Inhibin A — second-trimester screening marker (elevated in Down syndrome)
- Kisspeptin — produced in large quantities by placenta; regulates trophoblast invasion; plasma levels 1000-10000× non-pregnant
- PAPP-A (Pregnancy-Associated Plasma Protein A) — metalloprotease; cleaves IGFBP-4 → increases IGF bioavailability; first-trimester screening marker (low in Down syndrome)
6.4 Adrenal Medulla & Paraganglia (Neural Crest-Derived Chromaffin Tissue)
Function: Rapid stress response system (“fight-or-flight”). The adrenal medulla is a modified sympathetic ganglion — preganglionic sympathetic neurons synapse directly on chromaffin cells, which release catecholamines into the blood (endocrine, not neural). This is faster than hypothalamic-pituitary-adrenal cortisol (seconds vs minutes) and provides the immediate physiological response to acute stress: increased heart rate, blood pressure, bronchodilation, glucose mobilisation.
6.4.1 Adrenal Medulla (Modified Sympathetic Ganglion)
- Chromaffin cells — neural crest-derived; named for chromaffin reaction (brown colour with chromium salts due to catecholamine granules)
- Adrenaline (Epinephrine) — ~80% of output; produced only in adrenal medulla (requires PNMT which is cortisol-dependent — cortisol flows from cortex to medulla via cortical-medullary portal system)
- β1 effects — increased heart rate (chronotropy), contractility (inotropy), conduction velocity (dromotropy)
- β2 effects — bronchodilation, vasodilation (skeletal muscle), hepatic glycogenolysis, tremor
- α effects — vasoconstriction (at high doses, skin and splanchnic), pupil dilation (mydriasis)
- Noradrenaline (Norepinephrine) — ~20% of output; primarily α1 (vasoconstriction → blood pressure) and β1 (cardiac); less β2 than adrenaline; also the primary neurotransmitter of postganglionic sympathetic neurons
- PNMT (Phenylethanolamine N-methyltransferase) — converts noradrenaline → adrenaline; requires cortisol induction; explains why only adrenal medulla (bathed in cortisol-rich portal blood) produces significant adrenaline
- Adrenaline (Epinephrine) — ~80% of output; produced only in adrenal medulla (requires PNMT which is cortisol-dependent — cortisol flows from cortex to medulla via cortical-medullary portal system)
- Catecholamine biosynthesis: Tyrosine → L-DOPA (tyrosine hydroxylase, TH — rate-limiting) → Dopamine (AADC / aromatic L-amino acid decarboxylase) → Noradrenaline (DBH / dopamine β-hydroxylase, in vesicles) → Adrenaline (PNMT, in cytoplasm → re-enters vesicles)
- Other medullary products
- Dopamine (small amounts) — precursor; also released as minor secretory product
- Enkephalins (Met-enkephalin, Leu-enkephalin) — endogenous opioid peptides co-secreted with catecholamines; modulate pain and stress response
- Chromogranins (A, B) — acidic glycoproteins co-stored and co-secreted with catecholamines; chromogranin A is clinical marker for phaeochromocytoma and neuroendocrine tumours; processed to bioactive peptides (vasostatin, catestatin)
- Neuropeptide Y — potent vasoconstrictor; co-released with noradrenaline; modulates sympathetic tone
- Sustentacular cells (S-100 positive, support cells) — modified glial cells surrounding chromaffin cell clusters; paracrine support role; absent in phaeochromocytoma (diagnostic marker)
- Ganglion cells (scattered sympathetic neurons) — true postganglionic neurons interspersed among chromaffin cells
6.4.2 Extra-Adrenal Paraganglia
Function: Scattered clusters of chromaffin-like cells outside the adrenal medulla. Sympathetic paraganglia produce catecholamines; parasympathetic paraganglia function primarily as chemoreceptors (O₂, CO₂, pH sensing). Clinically relevant as sites of paraganglioma tumours.
Sympathetic Paraganglia (Catecholamine-Producing)
- Organ of Zuckerkandl (para-aortic, largest) — at aortic bifurcation; prominent in fetal life (primary catecholamine source before adrenal medulla matures); involutes after birth but tissue persists; most common site of extra-adrenal phaeochromocytoma in children
- Bladder wall paraganglia — can produce paroxysmal hypertension during micturition (bladder paraganglioma)
- Other retroperitoneal paraganglia — scattered along sympathetic chain and para-aortic region
- Catecholamine-producing (predominantly noradrenaline) — lack PNMT (no cortisol exposure) → produce noradrenaline, not adrenaline
Parasympathetic Paraganglia (Chemoreceptors)
- Carotid body (O2/CO2/pH chemoreceptor) — at carotid bifurcation; most important peripheral chemoreceptor; detects arterial PaO₂, PaCO₂, pH; drives ventilatory response to hypoxia
- Type I (glomus) cells — chemosensory; release dopamine, noradrenaline, serotonin, ACh in response to hypoxia → afferent signal via glossopharyngeal nerve → brainstem respiratory centres
- Type II (sustentacular) cells — glial-like support; modulate glomus cell sensitivity
- Aortic bodies — along aortic arch; similar chemoreceptor function; afferent via vagus nerve
- Jugulotympanic paraganglia — middle ear and jugular foramen; glomus tympanicum and jugulare tumours → pulsatile tinnitus, hearing loss
- Vagal paraganglia — along vagus nerve; chemoreceptor function
- Generally non-chromaffin — do not secrete catecholamines systemically; local neurotransmitter release only; tumours (paragangliomas) are usually non-functional
6.5 Adrenal Vasculature
Function: The adrenal’s unique vascular arrangement (cortical-medullary portal system) ensures that medullary chromaffin cells are bathed in cortisol-rich blood from the cortex. This is functionally critical: cortisol induces PNMT, the enzyme that converts noradrenaline to adrenaline. Without this vascular arrangement, the adrenal medulla would produce only noradrenaline.
- Superior adrenal arteries (from inferior phrenic) — multiple small branches; supply capsule and outer cortex
- Middle adrenal arteries (from aorta) — direct branches; supply mid-cortex
- Inferior adrenal arteries (from renal) — supply inner cortex and medulla
- Cortical sinusoids — blood flows centripetally: capsule → glomerulosa → fasciculata → reticularis → medulla; cortisol concentration increases progressively inward
- Adrenal vein: right → IVC directly (short, ~1 cm, easy to avulse during surgery); left → left renal vein (longer, with phrenic tributary)
7. Pancreatic Islets (Glucose Homeostasis)
Function: Moment-to-moment regulation of blood glucose within a narrow range (4-6 mmol/L fasting). The islet cells collectively sense blood glucose and release opposing hormones: insulin (lowers glucose) and glucagon (raises glucose). This dual control prevents both hypoglycaemia (seizures, coma, death) and hyperglycaemia (osmotic damage, ketoacidosis, vascular disease). The islets also regulate appetite, gut motility, and exocrine pancreatic function via paracrine signalling.
7.1 Islet Cell Types
7.1.1 Beta Cells (β-cells) — 60-80%
Function: Glucose sensor and insulin factory. Detect blood glucose via GLUT2 transporter and glucokinase (the “glucose sensor”). Glucose metabolism → ATP → closes KATP channels → depolarisation → Ca²+ influx → insulin granule exocytosis. First-phase (preformed granules, 5-10 min) and second-phase (newly synthesised, sustained) insulin release.
- Insulin — 51-amino acid peptide (A and B chains, disulfide-linked); half-life ~5 minutes
- Glucose uptake (GLUT4 translocation) — stimulates GLUT4 insertion in muscle and adipose cell membranes; does NOT affect brain (GLUT1, insulin-independent) or liver (GLUT2, insulin-independent)
- Glycogenesis, lipogenesis, protein synthesis — anabolic hormone; promotes storage of all fuel substrates
- Suppresses gluconeogenesis, glycogenolysis, lipolysis — inhibits catabolic pathways; net effect: blood glucose falls
- Amylin (IAPP — Islet Amyloid Polypeptide) — 37-amino acid peptide co-stored and co-secreted with insulin
- Slows gastric emptying — reduces rate of glucose absorption; prevents postprandial spikes
- Suppresses glucagon — prevents inappropriate hepatic glucose output after meals
- Aggregation into amyloid fibrils → islet amyloidosis in type 2 diabetes; progressive β-cell toxic
- C-peptide (byproduct of proinsulin cleavage) — equimolar with insulin; clinically useful: distinguishes endogenous insulin production (C-peptide present) from exogenous insulin injection (C-peptide absent); long half-life (~30 min) vs insulin (~5 min) makes it a better marker of β-cell secretion
7.1.2 Alpha Cells (α-cells) — 15-20%
Function: Counter-regulatory to β-cells. Activated by hypoglycaemia, amino acids, sympathetic stimulation. Suppressed by insulin (paracrine), somatostatin (paracrine), and hyperglycaemia. Glucagon acts primarily on the liver.
- Glucagon — 29-amino acid peptide; half-life ~5 minutes
- Glycogenolysis (liver) — rapid glycogen breakdown → glucose release; main mechanism for immediate glucose raising
- Gluconeogenesis (liver) — stimulates synthesis of glucose from amino acids, lactate, glycerol; sustained glucose maintenance
- Lipolysis, ketogenesis — mobilises fatty acids from adipose; hepatic β-oxidation → ketone bodies (acetoacetate, β-hydroxybutyrate); provides alternative fuel for brain during prolonged fasting; excess → diabetic ketoacidosis
7.1.3 Delta Cells (δ-cells) — 5-10%
Function: Local brake on both insulin and glucagon. Somatostatin acts as a paracrine “off switch” preventing excessive hormone swings. Also inhibits GI secretion and motility (same somatostatin as hypothalamic and GI forms).
- Somatostatin — 14-amino acid peptide (same as GI D-cell product)
- Paracrine inhibition of insulin and glucagon — prevents oscillation overshoot; fine-tunes glucose regulation
- Inhibits GI motility and secretion — slows nutrient absorption; basis of therapeutic somatostatin analogues (octreotide) for GI bleeding, acromegaly, neuroendocrine tumours
7.1.4 PP Cells (F-cells) — 1-2%
Function: Post-prandial regulation. Released after meals (especially protein-rich). Reduces appetite and inhibits exocrine pancreatic secretion. Concentrated in the head of the pancreas (embryological ventral pancreas origin).
- Pancreatic Polypeptide (PP) — 36-amino acid peptide
- Reduces appetite — central satiety effect via Y4 receptors in hypothalamus
- Inhibits pancreatic exocrine secretion — negative feedback on digestive enzyme output
- Inhibits gallbladder contraction — modulates bile release
7.1.5 Epsilon Cells (ε-cells) — <1%
Function: Appetite stimulation. Produce ghrelin within the islet, though the stomach is the primary ghrelin source. Role in islet development may be more significant than endocrine output in adults.
- Ghrelin (also produced in stomach — which produces >90%) — 28-amino acid peptide
- Appetite stimulation (orexigenic) — “hunger hormone”; rises before meals, falls after; acts on arcuate nucleus NPY/AgRP neurons
- GH secretagogue — stimulates GH release via GHS receptor; original discovery context (Growth Hormone Secretagogue)
7.2 Islet Architecture
Function: The spatial arrangement is not random — it optimises paracrine signalling. β-cells in the core are exposed to incoming arterial blood first, then blood flows outward past α and δ cells. This means insulin reaches α-cells at high concentration (paracrine suppression of glucagon). Disruption of islet architecture (as in type 2 diabetes, islet amyloidosis) impairs glucose regulation beyond what cell loss alone would explain.
- Core: β-cells (central) — first contact with arterial blood; insulin released downstream onto α/δ cells
- Mantle: α-cells, δ-cells (peripheral) — receive insulin-rich blood from core; paracrine regulation
- Dense capillary network (fenestrated endothelium) — 5-10× more vascular than surrounding exocrine tissue; allows rapid glucose sensing and hormone release
- Autonomic innervation — sympathetic (inhibits insulin via α2, stimulates glucagon via β2; “stress hyperglycaemia”), parasympathetic (stimulates insulin via muscarinic; “cephalic phase” insulin release before glucose rises), sensory (CGRP, substance P)
- ~1-2 million islets per pancreas — represent only 1-2% of pancreatic mass but receive 15-20% of pancreatic blood flow
- Islet-acinar portal system — islet hormones flow to surrounding exocrine tissue; insulin potentiates amylase synthesis; explains exocrine insufficiency in advanced type 1 diabetes
7.3 Pancreas Anatomy (Endocrine Context)
- Head (uncinate process) — PP-cell rich (ventral bud origin); closely applied to duodenal C-loop and common bile duct
- Neck — overlies superior mesenteric vessels; thin
- Body — crosses L1-L2; retroperitoneal
- Tail — extends to splenic hilum; highest islet density; most β-cell-rich region
- Main pancreatic duct (Wirsung) — joins common bile duct at ampulla of Vater; exocrine drainage
- Accessory duct (Santorini) — drains uncinate process and inferior head of pancreas; opens at minor duodenal papilla (~2 cm proximal to major papilla); functionally important as a safety valve: if the main duct (Wirsung) is obstructed (e.g., by tumour, stone, or stricture at the ampulla of Vater), the accessory duct provides alternative drainage preventing upstream pancreatic duct hypertension and pancreatitis; in pancreas divisum (~10% of population, most common congenital pancreatic anomaly), the accessory duct becomes the primary drainage route for the dorsal pancreas — if the minor papilla orifice is too narrow, this causes recurrent pancreatitis
8. Diffuse Neuroendocrine System (DNES)
Organisational note: These are hormone-producing cells embedded within non-endocrine organs. They synthesise and secrete into the bloodstream or paracrine space. The gut is arguably the largest endocrine organ by cell count. All entries below are producers, not receivers.
8.1 Gastrointestinal Enteroendocrine Cells
Function: The GI tract contains more endocrine cells than any other organ. They sense luminal contents (nutrients, pH, microbiota metabolites) and release hormones that coordinate digestion, absorption, metabolism, appetite, and gut motility. Many GI hormones also act as incretins (augment insulin release in response to oral glucose — the “incretin effect” explains why oral glucose provokes more insulin than IV glucose).
8.1.1 Stomach
- G-cells (antrum) → Gastrin — stimulates parietal cell HCl secretion (via ECL histamine release), gastric motility, mucosal growth; released by peptides in lumen, vagal stimulation (GRP); inhibited by somatostatin, low pH (<2); Zollinger-Ellison syndrome (gastrinoma → massive acid hypersecretion)
- ECL cells (Enterochromaffin-Like, fundus) → Histamine — stimulates parietal cells (H2 receptor → cAMP → H+/K+-ATPase); mediator of gastrin’s acid-stimulating effect; target of H2 blockers (ranitidine, famotidine)
- D-cells (antrum, fundus) → Somatostatin — paracrine inhibition of G-cells (gastrin), parietal cells (HCl), ECL cells (histamine); “acid brake”; released by low pH (negative feedback)
- P/D1 cells (fundus) → Ghrelin — appetite stimulation, GH secretion; primary source (>90% of circulating ghrelin); rises with fasting, drops after meals; vagal afferent signalling to hypothalamus
- EC cells (Enterochromaffin) → Serotonin (5-HT) — ~95% of body serotonin is in the gut; stimulates peristalsis (5-HT3, 5-HT4 receptors on enteric neurons), activates vagal afferents (nausea signalling); carcinoid tumours → serotonin excess (flushing, diarrhoea, bronchoconstriction)
8.1.2 Small Intestine
- I-cells (duodenum, jejunum) → CCK (Cholecystokinin) — gallbladder contraction (bile release), pancreatic enzyme secretion (acinar cells), delays gastric emptying, satiety (vagal afferents to NTS); released by fatty acids and amino acids in duodenal lumen; acts synergistically with secretin
- S-cells (duodenum) → Secretin — first hormone ever discovered (1902); stimulates pancreatic ductal bicarbonate secretion (neutralises gastric acid entering duodenum), hepatic bile flow (choleretic); released by duodenal acid (pH <4.5); inhibits gastrin
- K-cells (duodenum, jejunum) → GIP (Glucose-dependent Insulinotropic Peptide) — incretin: augments insulin secretion in response to oral glucose; also promotes fat storage (lipogenesis in adipose); originally named “Gastric Inhibitory Peptide” (inhibits gastric acid) but incretin effect is primary function; GIP receptor agonists used in type 2 diabetes treatment (tirzepatide = GIP+GLP-1 agonist)
- L-cells (ileum, colon) → GLP-1 (Glucagon-Like Peptide-1) — most important incretin; augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, promotes satiety (hypothalamic), β-cell proliferation/survival; rapidly degraded by DPP-4 (half-life ~2 min); GLP-1 receptor agonists (semaglutide, liraglutide) and DPP-4 inhibitors (sitagliptin) are major diabetes and obesity drugs
- L-cells → GLP-2 — intestinal growth factor; promotes mucosal integrity, villus height, crypt proliferation, intestinal blood flow; teduglutide (GLP-2 analogue) used for short bowel syndrome
- L-cells → PYY (Peptide YY) — satiety signal (“ileal brake”); reduces appetite (acts on arcuate nucleus Y2 receptors), slows gastric emptying, reduces intestinal motility; released by distal ileal and colonic L-cells after meals (especially fat-rich); PYY3-36 is the active form
- M-cells (duodenum) → Motilin — initiates migrating motor complex (MMC) during fasting; “housekeeper” of the gut (sweeps undigested material and bacteria distally); cyclic release every ~90 minutes in fasting state; erythromycin is a motilin receptor agonist (prokinetic use)
- EC cells → Serotonin (5-HT) — same as stomach; regulates motility and secretion throughout small intestine
- N-cells (ileum) → Neurotensin — released by fat in ileal lumen; modulates gut motility, stimulates pancreatic and biliary secretion, local trophic effects; may have systemic effects on blood pressure and body temperature
8.1.3 Large Intestine
- L-cells → GLP-1, PYY (major colonic source) — colonic L-cells are the primary source after distal ileal resection; respond to short-chain fatty acids (SCFAs) produced by microbiota fermentation (linking gut microbiome to metabolic regulation)
- EC cells → Serotonin — colonic serotonin drives motility; excess → diarrhoea (IBS-D, carcinoid); deficiency → constipation (IBS-C); 5-HT3 antagonists (ondansetron) and 5-HT4 agonists (prucalopride) treat motility disorders
- D-cells → Somatostatin — local paracrine brake on colonic secretion and motility
8.2 Pulmonary Neuroendocrine Cells
Function: Oxygen sensing and airway regulation. Rare cells scattered in airway epithelium. Produce local mediators affecting bronchial tone, mucosal blood flow, and immune responses. Clinically relevant as the cell of origin for small cell lung carcinoma.
- Pulmonary neuroendocrine cells (PNECs) — solitary or clustered; chemosensors for hypoxia, hypercapnia; secrete into submucosa
- Serotonin (5-HT) — bronchoconstriction, pulmonary vascular tone regulation
- Bombesin / GRP (Gastrin-Releasing Peptide) — fetal lung development (branching morphogenesis); adult: local mitogen; bombesin/GRP immunostaining used to diagnose small cell lung carcinoma
- Calcitonin Gene-Related Peptide (CGRP) — potent vasodilator; bronchoprotective; neurogenic inflammation
- Neuroepithelial bodies (NEBs) — organised clusters of PNECs at airway bifurcations; oxygen sensors (hypoxia → degranulation); innervated by vagal afferents; proposed stem cell niche for airway regeneration
8.3 Cardiac Endocrine Cells
Function: Volume and pressure regulation. Cardiac myocytes sense atrial stretch (volume overload) and release natriuretic peptides that promote sodium and water excretion, vasodilation, and oppose the RAAS system. Net effect: reduce blood volume and blood pressure. BNP is a cornerstone biomarker in heart failure diagnosis.
- Atrial cardiomyocytes → ANP (Atrial Natriuretic Peptide) — 28-amino acid; released by atrial wall stretch (volume overload); promotes natriuresis (renal sodium excretion via cGMP), vasodilation, suppresses renin and aldosterone secretion; reduces blood volume and pressure
- Ventricular cardiomyocytes → BNP (B-type Natriuretic Peptide) — 32-amino acid; released by ventricular wall stress (pressure and volume overload); same effects as ANP but more sustained; NT-proBNP (inactive N-terminal fragment) is the clinical biomarker for heart failure (elevated = ventricular dysfunction); nesiritide (recombinant BNP) used in acute decompensated heart failure
- CNP (C-type Natriuretic Peptide) — vascular endothelium and brain; primarily paracrine vasodilator; less natriuretic than ANP/BNP; important in vascular remodelling and endochondral bone growth
8.4 Renal Endocrine Function
Function: The kidney is both an endocrine target (aldosterone, ADH, PTH, ANP all act on it) and an endocrine organ. It produces renin (initiates RAAS for blood pressure control), EPO (drives red cell production), and active vitamin D (calcitriol, for calcium absorption). These three products regulate blood pressure, oxygen-carrying capacity, and mineral balance respectively.
- Juxtaglomerular cells (JG cells) → Renin — technically an enzyme, not a hormone (cleaves angiotensinogen → angiotensin I); released in response to reduced renal perfusion pressure (baroreceptor), sympathetic stimulation (β1), reduced NaCl at macula densa; initiates RAAS cascade → angiotensin II → aldosterone → sodium/water retention, vasoconstriction
- Peritubular interstitial cells → Erythropoietin (EPO) — glycoprotein hormone; released in response to renal hypoxia (HIF-2α pathway); stimulates erythroid progenitors in bone marrow → increased RBC production; 90% renal origin (10% hepatic); chronic kidney disease → EPO deficiency → anaemia of CKD; recombinant EPO (epoetin) for treatment; also abused in sport (blood doping)
- Proximal tubule cells → 1,25-Dihydroxyvitamin D3 (Calcitriol) — the active form of vitamin D; 1α-hydroxylase converts 25-OH-D3 (from liver) to 1,25-(OH)₂-D3; stimulated by PTH and low phosphate; suppressed by FGF23 and high calcium; increases intestinal calcium and phosphate absorption; CKD → calcitriol deficiency → secondary hyperparathyroidism, renal osteodystrophy
- Macula densa — specialised tubular cells at DCT/TAL junction; sense luminal NaCl concentration; signal to adjacent JG cells (tubuloglomerular feedback); low NaCl → increased renin release; paracrine signalling via adenosine, prostaglandins, NO
- Mesangial cells — contractile cells within glomerulus; regulate GFR by altering capillary surface area; respond to angiotensin II (contraction), ANP (relaxation); produce local prostaglandins and cytokines
8.5 Hepatic Endocrine Function
Function: The liver is the body’s metabolic command centre and a major endocrine organ. It produces growth mediators (IGF-1, IGF-2), iron regulators (hepcidin), blood pressure substrates (angiotensinogen), platelet regulators (TPO), and metabolic hormones (FGF21). Most of these are “endocrine at a distance” — hepatocytes release them into systemic circulation to act on distant organs.
- Hepatocytes → IGF-1 (Insulin-like Growth Factor 1) — mediates most of GH’s growth-promoting effects; GH stimulates hepatic IGF-1 production; IGF-1 feeds back to suppress pituitary GH; promotes linear growth, protein synthesis, cell survival; also produced locally in many tissues (paracrine)
- Hepatocytes → IGF-2 — fetal growth factor (less GH-dependent than IGF-1); imprinted gene (paternal allele); important in embryonic and placental growth; adult role less clear; overexpression in some tumours (non-islet cell tumour hypoglycaemia)
- Hepatocytes → IGFBP-1 to IGFBP-6 — six binding proteins that modulate IGF half-life and bioavailability; IGFBP-3 carries >75% of circulating IGF-1 in ternary complex (with ALS); insulin suppresses IGFBP-1 (low IGFBP-1 = insulin resistance marker)
- Hepatocytes → Hepcidin — 25-amino acid peptide; master regulator of iron homeostasis; binds ferroportin (iron exporter on enterocytes, macrophages, hepatocytes) → internalisation and degradation → reduces iron absorption and release; increased by iron excess and inflammation (IL-6); decreased by iron deficiency, hypoxia, EPO; hepcidin excess → anaemia of chronic disease; hepcidin deficiency → haemochromatosis
- Hepatocytes → Angiotensinogen — 452-amino acid protein; constitutively secreted; substrate for renin (→ angiotensin I → ACE → angiotensin II); liver is primary source but adipose tissue also produces it (contributes to obesity-related hypertension)
- Hepatocytes → Thrombopoietin (TPO) — constitutively produced; stimulates megakaryocyte proliferation and platelet production; plasma level inversely proportional to platelet mass (platelet binding removes TPO → low platelets = high TPO → stimulates production; high platelets = low TPO)
- Hepatocytes → FGF21 (Fibroblast Growth Factor 21) — metabolic hormone; released during fasting, exercise, ketogenic diet; promotes fatty acid oxidation, ketogenesis, glucose uptake; improves insulin sensitivity; induces browning of WAT; analogue drugs in clinical trials for NASH and obesity
- Kupffer cells → cytokines (paracrine/endocrine cross-talk) — resident macrophages; produce IL-6, TNF-α, IL-1 in response to gut-derived endotoxin (portal circulation); hepatic IL-6 is major driver of CRP and acute phase protein production
9. Endocrine Tissues (Non-Glandular Hormone Producers)
Organisational note: These are mesenchymal, connective, and epithelial tissues recognised (largely in the last 20 years) as having significant endocrine function. They are distinct from the DNES (§8) because they are not neuroendocrine cells — they are structural/metabolic tissues that also secrete hormones.
9.1 Adipose Tissue
Function: Far more than energy storage. Adipose tissue is now recognised as the body’s largest endocrine organ by mass. Adipokines regulate appetite, insulin sensitivity, inflammation, vascular function, and reproduction. Excess adipose tissue (obesity) creates a pro-inflammatory, insulin-resistant endocrine environment — many metabolic diseases are fundamentally diseases of adipose endocrine dysfunction.
9.1.1 White Adipose Tissue (WAT) — Adipokines
- Leptin — 16 kDa protein; the “satiety hormone”; production proportional to fat mass; acts on arcuate nucleus ObRb receptors → suppresses NPY/AgRP (appetite), activates POMC/CART (satiety); resistance develops in obesity (high leptin but no satiety effect — “leptin resistance”); also signals reproductive sufficiency (low leptin → amenorrhoea in underweight women)
- Adiponectin — most abundant adipokine (5-30 μg/mL); paradoxically decreased in obesity (inverse correlation with fat mass); insulin sensitiser (activates AMPK in muscle and liver), anti-inflammatory (suppresses TNF-α, IL-6), cardioprotective (anti-atherogenic), anti-fibrotic; high adiponectin = metabolic health; low = metabolic syndrome risk
- Resistin — insulin resistance promoter; named for “resistance to insulin”; pro-inflammatory; more significant in rodents than humans; in humans, mainly from macrophages in adipose tissue rather than adipocytes
- Visfatin (NAMPT) — nicotinamide phosphoribosyltransferase; enzyme for NAD+ biosynthesis; insulin-mimetic (binds insulin receptor); elevated in visceral obesity and inflammation; dual intracellular (enzymatic) and extracellular (cytokine-like) functions
- Apelin — peptide ligand for APJ receptor; cardiovascular regulation (positive inotrope, vasodilator), glucose metabolism (enhances insulin sensitivity), fluid homeostasis (suppresses ADH release)
- Omentin — preferentially produced by visceral omental fat; insulin sensitiser; anti-inflammatory; decreased in obesity and type 2 diabetes; higher in subcutaneous than visceral fat
- RBP4 (Retinol-Binding Protein 4) — elevated in insulin resistance and visceral obesity; impairs insulin signalling in muscle; proposed link between vitamin A metabolism and metabolic syndrome
- PAI-1 (Plasminogen Activator Inhibitor-1) — inhibits fibrinolysis (prothrombotic); elevated in visceral obesity → increased cardiovascular thrombotic risk; contributes to the prothrombotic state of metabolic syndrome
- TNF-α, IL-6 — pro-inflammatory cytokines from adipose tissue macrophages (crown-like structures around dead adipocytes); TNF-α impairs insulin receptor signalling (serine phosphorylation of IRS-1); IL-6 drives hepatic CRP production; chronic low-grade inflammation of obesity
- Angiotensinogen — local RAAS in adipose; adipose-derived angiotensin II promotes adipogenesis, vasoconstriction; contributes to obesity-related hypertension independent of renal RAAS
- Oestrogens (aromatase activity) — peripheral conversion of adrenal androgens (androstenedione → oestrone); primary oestrogen source post-menopause; obesity → excess oestrogen → increased breast and endometrial cancer risk; also explains gynaecomastia in obese males
9.1.2 Brown Adipose Tissue (BAT) — Batokines
Function: Thermogenesis — BAT burns fatty acids to generate heat (non-shivering thermogenesis) via UCP1 uncoupling of the mitochondrial proton gradient. Active in infants (thermoregulation), rediscovered in adults (2009, PET-CT studies). BAT activation improves glucose and lipid metabolism. BAT secretes its own endocrine products (batokines).
- FGF21 — BAT-derived FGF21 promotes thermogenesis, browning of WAT, insulin sensitivity; also hepatic (see §8.5)
- Neuregulin 4 (NRG4) — hepatoprotective; suppresses hepatic lipogenesis; anti-inflammatory; reduced in NAFLD/NASH
- 12,13-diHOME — lipokine released by BAT during exercise and cold exposure; promotes fatty acid uptake into BAT and muscle; may mediate some metabolic benefits of exercise
- UCP1 (Uncoupling Protein 1) — not secreted; the defining protein of BAT; uncouples electron transport chain → proton leak → heat instead of ATP; activated by noradrenaline (β3 receptors), free fatty acids, cold exposure
- BMP8b — bone morphogenetic protein 8b; central (hypothalamic) and peripheral thermogenesis signalling; sensitises BAT to noradrenergic stimulation
9.1.3 Beige/Brite Adipocytes
Function: Inducible thermogenic cells within WAT depots. “Browning” of WAT — white adipocytes can be converted to beige cells that express UCP1 and generate heat. This is a therapeutic target for obesity (increase energy expenditure). Induced by cold, exercise (irisin), catecholamines (β3), thyroid hormones, and certain drugs.
- Inducible thermogenic cells within WAT depots — scattered among white adipocytes; multilocular lipid droplets (like BAT) rather than unilocular (WAT)
- UCP1 expression upon stimulation (cold, exercise, β3-agonism) — gene expression driven by PGC-1α, PRDM16; reversible (beige → white if stimulus removed)
9.2 Bone — Osteokines
Function: Bone is a metabolically active endocrine organ, not an inert scaffold. Osteoblasts and osteocytes secrete hormones that regulate phosphate balance (FGF23), glucose metabolism (osteocalcin), and bone remodelling (sclerostin, RANKL/OPG). The skeleton communicates bidirectionally with pancreas, kidney, muscle, and brain.
- Osteocalcin (osteoblasts) — most abundant non-collagenous bone protein; undercarboxylated form (ucOC) is the hormonally active form; stimulates insulin secretion (pancreatic β-cells), testosterone production (Leydig cells), and neuronal neurotransmitter synthesis (serotonin, catecholamines); exercise increases ucOC; potential link between exercise, bone health, and metabolic/cognitive benefits
- FGF23 (osteocytes) — phosphate-regulating hormone; promotes renal phosphate excretion (downregulates NaPi-IIa/c transporters in proximal tubule); suppresses 1α-hydroxylase (reduces calcitriol); co-receptor: Klotho (renal); CKD → FGF23 excess → phosphate wasting, vitamin D deficiency → secondary hyperparathyroidism cascade; excess: tumour-induced osteomalacia; genetic excess: autosomal dominant hypophosphatemic rickets
- Sclerostin (osteocytes, SOST gene) — glycoprotein; inhibits Wnt signalling in osteoblasts → suppresses bone formation; mechanosensitive (mechanical loading suppresses sclerostin → permits bone formation; disuse increases sclerostin → bone loss); romosozumab (anti-sclerostin antibody) used for severe osteoporosis
- RANKL (osteoblasts/osteocytes) — Receptor Activator of NF-κB Ligand; essential for osteoclast differentiation, activation, and survival; binds RANK on osteoclast precursors → osteoclastogenesis; the “bone resorption signal”; denosumab (anti-RANKL antibody) used for osteoporosis
- OPG (Osteoprotegerin) — decoy receptor secreted by osteoblasts; binds RANKL, prevents it from activating RANK → inhibits osteoclast formation; RANKL/OPG ratio determines net bone resorption vs formation; oestrogen stimulates OPG production (oestrogen deficiency → low OPG → increased RANKL → post-menopausal bone loss)
9.3 Skeletal Muscle — Myokines
Function: Exercising muscle is an endocrine organ. Myokines are cytokines and peptides released by contracting muscle fibres that mediate systemic effects of exercise: anti-inflammatory action, fat browning, insulin sensitivity, neuroprotection, and bone-muscle cross-talk. This explains many “exercise-as-medicine” benefits at a molecular level.
- IL-6 — the prototypical exercise myokine; released in proportion to exercise duration and muscle mass engaged; exercise-derived IL-6 is anti-inflammatory (different from obesity-derived IL-6 which is pro-inflammatory — context matters: acute pulsatile release = beneficial, chronic elevation = harmful); stimulates hepatic glucose output during exercise, promotes lipolysis, induces IL-10 and IL-1ra (anti-inflammatory cascade)
- Irisin (FNDC5 cleavage) — released during exercise; promotes browning of WAT (white→beige adipocyte conversion → UCP1 expression → thermogenesis); improves insulin sensitivity; enhances BDNF expression in hippocampus (exercise→brain benefit pathway); named after Iris, Greek messenger goddess
- Myostatin (GDF-8) — negative regulator of muscle mass; inhibits myoblast proliferation and differentiation; myostatin-null animals → extreme muscular hypertrophy (Belgian Blue cattle, whippet “bully” phenotype); therapeutic target: anti-myostatin antibodies for sarcopenia and muscular dystrophies
- IL-15 — promotes NK cell function and maintenance; stimulates lipid oxidation in adipose tissue (muscle→fat cross-talk); resistance exercise increases IL-15; associated with reduced visceral fat
- BDNF — brain-derived neurotrophic factor; muscle contraction increases circulating BDNF; promotes neurogenesis (hippocampus), synaptic plasticity, memory; major mediator of exercise-induced cognitive improvement; decreased in depression, Alzheimer’s (exercise as therapeutic)
- Meteorin-like (METRNL) — released by muscle during exercise and by adipose during cold exposure; promotes WAT browning, enhances thermogenesis; anti-inflammatory (induces eosinophil recruitment and IL-4/IL-13 → M2 macrophage polarisation)
- BAIBA (β-aminoisobutyric acid) — thymine catabolite released during exercise; promotes WAT browning, improves insulin sensitivity, enhances fatty acid oxidation; associated with reduced cardiometabolic risk in epidemiological studies
9.4 Skin
Function: The skin is the body’s primary vitamin D synthesis site. UVB radiation initiates the first step of vitamin D activation. The skin also produces antimicrobial peptides that function as local endocrine/paracrine effectors in innate immunity.
- Vitamin D3 (Cholecalciferol) — 7-dehydrocholesterol (in epidermal keratinocytes) + UVB (290-315 nm) → previtamin D3 (photolysis) → vitamin D3 (thermal isomerisation); then to liver (25-hydroxylation → calcidiol) → kidney (1α-hydroxylation → calcitriol, the active hormone); latitude, skin pigmentation, sunscreen, age, and season all affect synthesis; at >37°N/S latitude, UVB is insufficient for synthesis in winter months
- Cathelicidin (LL-37) — antimicrobial peptide; vitamin D induces cathelicidin gene expression in keratinocytes and macrophages; broad-spectrum antimicrobial (bacteria, fungi, viruses, mycobacteria); disrupts microbial membranes; vitamin D deficiency → reduced LL-37 → increased infection susceptibility (tuberculosis link)
- Dermcidin — constitutively secreted by eccrine sweat glands; antimicrobial peptide active in sweat; provides continuous skin surface defence independent of vitamin D or immune activation; effective against S. aureus, E. coli, Candida
9.5 Thymus (Endocrine Function)
Function: Beyond its lymphoid role (T-cell maturation, see Lymphatic System §1.1), the thymus produces peptide hormones that promote T-cell differentiation, immune competence, and tissue repair. Thymic endocrine function declines with age (involution) but persists at reduced levels throughout life.
9.5.1 Thymic Hormones / Peptides
- Thymosin α1 — 28-amino acid peptide; enhances T-cell maturation, dendritic cell function, and NK cell activity; immunotherapy applications: approved in some countries for hepatitis B/C, as vaccine adjuvant, and for immune reconstitution in immunodeficiency
- Thymosin β4 — 43-amino acid peptide; intracellular G-actin sequestering protein; extracellular: wound healing (promotes angiogenesis, cell migration, collagen deposition), anti-inflammatory, cardioprotective (reduces scar size post-MI in animal models)
- Thymulin (FTS — Facteur Thymique Sérique) — nonapeptide; uniquely zinc-dependent (inactive without Zn²⁺); promotes T-cell differentiation (CD4/CD8 expression); serum levels decline with age and zinc deficiency; zinc supplementation can partially restore thymulin activity in elderly
- Thymopoietin (TP) — 49-amino acid peptide; induces T-cell differentiation markers; also affects neuromuscular junction (binds acetylcholine receptors → may contribute to myasthenia gravis-thymoma association)
- Thymic Stromal Lymphopoietin (TSLP) — IL-7-like cytokine; produced by thymic epithelial cells (also keratinocytes, bronchial epithelium); activates dendritic cells → drives Th2 responses; promotes Treg generation in thymus; overexpression linked to allergic inflammation (asthma, atopic dermatitis)
9.5.2 Thymic Involution
- Peaks at puberty, progressive adipose replacement — active lymphoepithelial tissue replaced by fat; thymic mass decreases ~3%/year after puberty; by age 50, ~80% adipose
- Sex steroids accelerate involution — testosterone and oestrogen both promote thymic atrophy; castration in animal models reverses involution (basis of research into immune rejuvenation)
- Residual endocrine function persists into adulthood — small islands of thymic tissue continue producing thymulin, thymosin; sufficient for maintenance T-cell production; severe stress or illness can further deplete residual thymic function
10. Endocrine Cross-Talk (Inter-System Regulatory Interfaces)
Organisational note: This section maps the bidirectional signalling between the endocrine system and other major systems (immune, nervous). These are not discrete glands or tissues but regulatory interactions that modulate multiple systems simultaneously.
10.1 Immune-Endocrine Interface
Function: The immune and endocrine systems communicate bidirectionally. Cytokines from immune cells activate endocrine axes (especially HPA → cortisol), and hormones modulate immune cell function, proliferation, and cytokine production. This interface explains why stress suppresses immunity, why autoimmune diseases have sex differences, and why chronic inflammation causes metabolic disease.
10.1.1 Cytokines with Endocrine Effects (Immune → Endocrine)
- IL-1 — potent HPA axis activator (CRH stimulation); induces fever via hypothalamic PGE2; suppresses HPG axis (stress-induced reproductive suppression); stimulates hepatic acute phase proteins
- IL-6 — most important immune-endocrine cytokine; activates HPA axis (CRH and direct pituitary ACTH stimulation); drives hepatic acute phase response (CRP, fibrinogen, hepcidin); induces insulin resistance (impairs insulin receptor signalling); stimulates adrenal cortisol and catecholamine production
- TNF-α — cachexia (muscle wasting via ubiquitin-proteasome activation); insulin resistance (serine phosphorylation of IRS-1); fever; bone resorption (synergises with RANKL); suppresses appetite (anorexia of chronic disease); inhibits thyroid function
- IL-2 — T-cell growth factor; also activates HPA axis; stimulates GH and prolactin release; enhances NK cell and macrophage activity
- Interferon-γ — macrophage activation; induces thyroid MHC-II expression (autoimmune thyroiditis susceptibility); activates IDO (tryptophan → kynurenine pathway → serotonin depletion → depression in chronic inflammation)
10.1.2 Hormonal Immunomodulation (Endocrine → Immune)
- Cortisol — most potent endogenous immunosuppressant; induces lymphocyte apoptosis (especially T-cells), redistributes lymphocytes from blood to tissues, suppresses NF-κB → reduces pro-inflammatory cytokines (IL-1, IL-6, TNF-α), inhibits prostaglandin synthesis; chronic excess (Cushing’s) → opportunistic infections; basis of therapeutic corticosteroids
- DHEA — immune enhancement; opposes cortisol; enhances IL-2 production, T-cell proliferation, NK cell activity; cortisol/DHEA ratio may be more important than absolute cortisol level (high ratio = immunosuppression); declines with age → “immunosenescence” component
- Oestrogens — complex: low/physiological levels enhance immune function (higher antibody responses, stronger T-cell activation); explains why females mount stronger immune responses and have higher autoimmune disease prevalence (SLE, RA, MS, Hashimoto’s — all female-predominant); pregnancy (high oestrogen) paradoxically shifts toward Th2/tolerance
- Testosterone — mild immunosuppression; reduces pro-inflammatory cytokines, decreases antibody production; explains males’ higher susceptibility to infections but lower autoimmune risk; castration improves immune responses in animal models
- Vitamin D — immune regulation; promotes Treg differentiation (tolerance), induces cathelicidin (antimicrobial), suppresses Th17 and Th1 responses; deficiency linked to autoimmune disease risk (MS, type 1 diabetes, RA) and infection susceptibility (tuberculosis)
- Melatonin — immune enhancement; enhances Th1 responses, NK cell cytotoxicity, IL-2 production; opposes cortisol’s immunosuppressive effect; shift workers (disrupted melatonin) have increased infection and cancer rates
- Leptin — pro-inflammatory; activates monocytes/macrophages, promotes Th1 differentiation, enhances neutrophil chemotaxis; leptin deficiency (starvation, lipodystrophy) → immunodeficiency; obesity (leptin resistance) → chronic inflammation
- GH / IGF-1 — thymic growth and T-cell development; immune reconstitution; GH promotes thymic regrowth in aged or thymus-atrophied subjects; GH-deficient individuals have impaired immune function (reversed by replacement)
10.2 Neuroendocrine Signalling Molecules
Function: Molecules produced by neurons that have systemic hormonal effects, blurring the line between nervous and endocrine systems. Many serve dual roles: neurotransmitter within the CNS and hormone/paracrine factor in the periphery. They regulate pain, appetite, reproduction, vascular tone, and stress responses.
10.2.1 Neuropeptides with Endocrine Relevance
- Substance P — 11-amino acid tachykinin; pain transmission (C-fibres → dorsal horn); neurogenic inflammation (vasodilation, plasma extravasation, mast cell degranulation); immune activation (stimulates macrophage cytokine production); mood regulation (elevated in anxiety/depression)
- CGRP (Calcitonin Gene-Related Peptide) — alternatively spliced product of calcitonin gene; most potent endogenous vasodilator; released from trigeminal sensory neurons → meningeal vasodilation (migraine pathophysiology); CGRP receptor antagonists (gepants) and anti-CGRP antibodies (erenumab, galcanezumab) are major migraine preventive drugs
- VIP (Vasoactive Intestinal Peptide) — 28-amino acid; vasodilation, smooth muscle relaxation (bronchi, GI), stimulates intestinal water and electrolyte secretion, pancreatic bicarbonate secretion; co-transmitter with ACh in parasympathetic neurons; VIPoma → watery diarrhoea, hypokalaemia, achlorhydria (WDHA/Verner-Morrison syndrome)
- NPY (Neuropeptide Y) — 36-amino acid; most abundant neuropeptide in brain; potent orexigenic (appetite stimulant — arcuate → PVN pathway); peripheral vasoconstrictor (co-released with noradrenaline from sympathetic nerves); anxiolytic (Y1 receptor); involved in stress resilience, circadian rhythm, bone metabolism
- Orexin A & B (Hypocretin 1 & 2) — produced only in lateral hypothalamus (~70,000 neurons); promote wakefulness, appetite, reward-seeking; stabilise sleep-wake transitions; loss of orexin neurons → narcolepsy type 1 (autoimmune destruction); orexin receptor antagonists (suvorexant, lemborexant) used as sleep aids
- Galanin — 29-amino acid; co-localised with many neurotransmitters; modulates feeding (orexigenic in hypothalamus), cognition (inhibits cholinergic transmission — memory impairment), pain (analgesic in spinal cord), mood (anxiogenic); galanin hyperinnervation of basal forebrain in Alzheimer’s disease
- PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) — VIP superfamily; neuroprotection (anti-apoptotic in neurons), stress response (activates HPA axis), vasodilation; emerging role in migraine (PACAP infusion triggers migraine attacks; anti-PACAP antibodies in clinical trials)
10.2.2 Reproductive Neuroendocrine Regulators
- Kisspeptin — essential gatekeeper of puberty and fertility; produced by KNDy neurons in arcuate nucleus and AVPV; directly stimulates GnRH neurons (most potent GnRH secretagogue known); loss-of-function mutations → hypogonadotropic hypogonadism (no puberty); gain-of-function → precocious puberty; integrates metabolic status (leptin), stress (cortisol), and photoperiod (melatonin) with reproductive axis; kisspeptin agonists in clinical trials for infertility
- Neurokinin B — tachykinin co-expressed with kisspeptin in KNDy neurons; stimulates kisspeptin release (autocrine/paracrine); mutations in NKB or NK3R → hypogonadotropic hypogonadism; NK3R antagonists being studied for hot flashes in menopause (fezolinetant approved)
- Dynorphin — endogenous κ-opioid; co-expressed in KNDy neurons; inhibits kisspeptin release (negative arm of GnRH pulse generator); KNDy neuron model: kisspeptin (stimulate) + NKB (stimulate) + dynorphin (inhibit) = pulsatile GnRH output; also: analgesia, dysphoria, diuresis
10.2.3 Endogenous Opioids & Cannabinoids
- β-Endorphin (from POMC) — 31-amino acid; μ-opioid receptor agonist; produced in arcuate nucleus and anterior pituitary; analgesia (30× more potent than morphine), euphoria (“runner’s high”), stress-induced analgesia; inhibits GnRH release (stress-reproductive suppression); co-released with ACTH from corticotrophs
- Enkephalins (Met- and Leu-) — pentapeptides; δ-opioid receptor preference; distributed widely in CNS and adrenal medulla; modulate pain (spinal gate control), mood, GI motility (μ-receptor activation in gut → constipation — basis of opioid-induced constipation); co-released with catecholamines from chromaffin cells
- Endocannabinoids (AEA/anandamide, 2-AG) — lipid-based retrograde signalling molecules; produced on demand (not stored in vesicles); act on CB1 (CNS: pain, appetite, mood, memory) and CB2 (immune cells: anti-inflammatory) receptors; appetite stimulation (hypothalamic CB1 → “munchies”), pain modulation (descending inhibition), mood regulation (anxiolytic), immune modulation (suppress pro-inflammatory cytokines); endocannabinoid tone disrupted in obesity, chronic pain, depression; rimonabant (CB1 inverse agonist) withdrawn due to psychiatric side effects